You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康泰生物(300601.SZ)麻腮風聯合減毒活疫苗臨牀試驗申請獲得受理
格隆匯 10-16 22:02

格隆匯10月16日丨康泰生物(300601.SZ)公佈,公司全資子公司北京民海生物科技有限公司(以下簡稱"民海生物")近日收到國家藥品監督管理局簽發的受理通知書,同意受理民海生物研發的麻腮風聯合減毒活疫苗臨牀試驗申請。

本次獲得麻腮風聯合減毒活疫苗的臨牀試驗受理通知書,表明公司在多聯疫本公司及董事會全體成員保證信息披露的內容真實、準確、完整,沒有虛假記載、誤導性陳述或重大遺漏。苗領域又一重要研發項目取得新進展,有利於進一步豐富公司產品佈局,增強公司的核心競爭力和市場地位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account